OGEN

Oragenics is a development-stage biopharma with no meaningful product revenue (FY2023 revenue of just $37.7K, nothing since) and a single clinical bet: ONP-002, an intranasal neurosteroid for mild traumatic brain injury. The MD&A is explicit that management has 'substantial doubt about our ability to continue as a going concern within one year,' backed by a $226.6M accumulated deficit and net losses of $9.8M (2025) and $10.6M (2024). This is not a business yet — it is a research program that survives on serial capital raises.

The balance sheet makes the timing problem acute. Cash was only $4.40M at 12/31/2025 against an operating cash burn of $9.25M per year — less than six months of runway from year-end, and the latest 10-Q (period 2026-03-31) means that clock has already run further down. The company has already leaned on every dilutive lever available: a February 2025 ATM sale (258,849 shares, $2.6M net), a $3.0M promissory note issued at a punitive 17% original-issue discount, and a July 2025 Series H convertible preferred offering with warrants (~$15M net). With a market cap of just $2.54M on 4.34M shares (already reverse-split, shares down ~80% YoY), the next raise needed to fund Phase 2 will be enormously dilutive to existing holders, and the outstanding Series H preferred and warrants are a standing overhang.